Riboflavin presents tremendous potential as a photosensitizing agent for photodynamic therapy (PDT) for treating microbial infection and cancer therapy. Encapsulation of riboflavin can improve its bioavailability and stability while making the clinical applications more efficient. The authors' detailed study on cellular inhibition of liposome encapsulated riboflavin-5-phosphate investigation, and the effect of unencapsulated riboflavin on liposome bilayers aims to improve the efficiency of cellular delivery of riboflavin. Nano-sized liposomes composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol were used in this study. Cell studies demonstrate high inhibition rates for the lipsome-encapsualted high concentration riboflavin formulations in the presence of blue light, despite the lower encapsulation lading.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: